Gao JJ, Prowell TM, Gittleman H, Cheng J, et al. US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting. J Clin Oncol 2025 Aug 11:JCO2500167. doi: 10.1200/JCO-25-00167.
PMID: 40789109